loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for VS-6766

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    VS-6766

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
    Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer

    29 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240729473398/en

    BUSINESSWIRE
    29 Jul 2024
    Share Share
    ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success
    ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success

    25 May 2024

    // Robert Barrie CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/asco-2024-verastems-combo-therapy-for-pancreatic-cancer-hits-early-trial-success/#:~:text=clinical%20research%20companies-,ASCO%202024%3A%20Verastem\'s%20combo%20therapy%20for%20pancreatic%20cancer%20hits%20early,%25%20in%20pre%2Dmarket%20trading.&text=Verastem%20will%20present%20the%20results,Meeting%20on%201%20June%202024.

    Robert Barrie CLINICALTRIALSARENA
    25 May 2024
    Share Share
    Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone
    Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone

    05 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240305616374/en

    BUSINESSWIRE
    05 Mar 2024
    Share Share
    Verastem Oncology Outlines Key 2024 Strategic Priorities
    Verastem Oncology Outlines Key 2024 Strategic Priorities

    29 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240124822477/en

    BUSINESSWIRE
    29 Jan 2024
    Share Share
    Verastem Granted Fast Track Designation for Avutometinib and Sotorasib
    Verastem Granted Fast Track Designation for Avutometinib and Sotorasib

    18 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240118664635/en

    BUSINESSWIRE
    18 Jan 2024
    Share Share
    Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib
    Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib

    13 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231213489476/en

    BUSINESSWIRE
    13 Dec 2023
    Share Share